Stock Movers Figma Surges, Moderna Falls, Coinbase Drops on Earnings Miss
Aug 1, 2025
Figma's blockbuster IPO raises its co-founder to near billionaire status as shares soar. Meanwhile, Moderna struggles with a dip in sales and lowers its revenue forecast, reflecting challenges in post-Covid market dynamics. Coinbase faces backlash after missing revenue estimates due to sluggish retail trading, signaling a cooling in the crypto market. The podcast dives into these contrasting financial outcomes and offers insights into the stock performances of these key players.
AI Snips
Chapters
Transcript
Episode notes
Figma's Record-Breaking IPO
- Figma's IPO was extremely successful, marking the largest first-day trading gain for a US-listed company in about 30 years that raised over a billion dollars.
- This IPO made co-founder Dylan Field one of the world's richest people with a fortune of $6.1 billion.
Moderna Earnings and Forecast Hit
- Moderna's stock fell over 7% after reporting a 41% sales drop year over year, driven by lower COVID-19 vaccine sales.
- The company also lowered its high-end revenue forecast due to shifting contract revenue timing to 2026.
Watch Moderna's Cash Flow Risks
- Investors should watch Moderna carefully as cash flow risk may increase if its cancer program with Merck fails.
- Pay attention to timing shifts in contract revenue since they directly affect revenue forecasts.